Another vital step in the direction of the success of ICVAX®
HONG KONG SAR – Media OutReach Newswire – 27 May 2026 – Immuno Cure Group (“Immuno Cure“), headquartered at Hong Kong Science Park, is happy to announce the inauguration of the analysis facility for its HIV therapeutic DNA vaccine (“ICVAX®“) at the Center of International Innovation for Technology and Science (“CIITS”) positioned in Hetao, Shenzhen. The facility goals for the event and software of key applied sciences for the scientific analysis and commercialization of Immuno Cure’s ICVAX®. ICVAX® is developed by Immuno Cure with the purpose of reaching antiretroviral remedy (“ART“)-free practical remedy for HIV an infection. This challenge is carried out in collaboration with Prof. Zhiwei CHEN, the Founding Director of the AIDS Institute of Li Ka Shing Faculty of Medicine, the University of Hong Kong (“HKU AIDS Institute“), and Prof. Hongzhou LU, President of the Third People’s Hospital of Shenzhen, within the capability as advisors.
CIITS is a national-level achievement transformation platform co-built by Guangdong Province, Shenzhen Municipality, and Tsinghua University, and is positioned at the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone (“Hetao Co-operation Zone“). It is dedicated to constructing a world’s main main technological innovation and industrialization platform with a worldwide perspective. It focuses on key tracks together with biomedicine, high-performance supplies, and synthetic intelligence (AI). It goals to mixture world innovation assets, join with main enterprises, and conduct organized scientific analysis and achievement transformation to deal with nationwide main strategic wants.
Since AIDS was first recognized in 1981, 40.8 million folks have died from HIV an infection, with over 44.1 million folks dwelling with HIV globally. While antiretroviral remedy can successfully management HIV replication, it can’t remedy the illness, highlighting the crucial want for immunotherapies. Designed to improve the host’s immune response, immunotherapies purpose to obtain sustained viral management with out lifelong ART, finally main to full viral suppression and practical remedy. Immuno Cure’s proprietary modern HIV therapeutic DNA vaccine, ICVAX®, induces broad-spectrum, polyfunctional virus-specific T cells to obtain the last word purpose of ART-free practical remedy of HIV an infection.
Immuno Cure accomplished the first-in-human Phase I scientific trial of ICVAX® in November 2024, demonstrating glorious security and promising immunogenicity. Two multi-center Phase II scientific trials—randomized, double-blind, and placebo-controlled—are scheduled to launch in Q2-2026 to consider the vaccine’s mechanism of motion and efficacy. The trials shall be performed at Prince of Wales Hospital in Hong Kong, in addition to eight top-tier hospitals in China, together with the Shenzhen Third People’s Hospital, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing Youan Hospital affiliated to Capital Medical University, the Eighth People’s Hospital of Guangzhou, the Second People’s Hospital of Tianjin, the Sixth People’s Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center.
Notably, standardized testing programs for evaluating immunological and virological indicators are essential for HIV vaccine scientific trials. However, the dearth of home customary working procedures (SOPs) for infectious samples in scientific trials hinders the scientific growth and regulatory approval of novel infectious illness therapies like ICVAX®. The mission of this analysis facility at CIITS is to set up an internationally aligned standardized scientific testing system for T-cell immunogenicity and viral reservoirs, in addition to establish core biomarkers related to vaccine efficacy — filling a home technical hole. Immuno Cure will provide the ICVAX® Phase II scientific trial to facilitate the event of this standardized precision testing methodology for scientific pattern evaluation.
Dr. Xia JIN, CEO of Immuno Cure, acknowledged, “I’m delighted to be appointed to lead this key challenge of CIITS. I might additionally like to thank CIITS for the absolutely fitted trendy laboratory house and the RMB10.0m funding assist for this 2-year preliminary part. My entire scientific crew is dedicated to contributing diligently to the success of this challenge. I’ve little question that the event of a standardised testing regime wouldn’t solely improve the standard of our scientific trials for ICVAX® however would additionally ultimately be adopted as trade and nationwide requirements for the scientific translation of medication for HIV/AIDS and different infectious ailments.
Renchen LIU, Executive Deputy Dean of Research Institute of Tsinghua University in Shenzhen and Director of CIITS, acknowledged, “Warmest congratulations on the inauguration of the research facility for ICVAX® at the CIITS. In the future, CIITS will continue to leverage its platform resources to implement full-chain incubation services. Project managers will provide service support throughout the entire project period, ensuring the smooth progress of the project through resource integration, talent recruitment and development, clinical collaboration, and achievement transformation. These efforts will safeguard the steady progress of the project.”
As the challenge advances, Immuno Cure’s ICVAX® is positioned to develop into the world’s first therapeutic DNA vaccine to ship an ART-free practical remedy for HIV an infection, bringing new hope to folks at the moment dwelling with HIV. In parallel, the standardized testing platform and collaborative innovation mannequin developed via this effort will present a scalable, replicable blueprint for R&D of novel therapies focusing on different main infectious ailments. Together, these outcomes will strengthen the worldwide competitiveness of biomedicine growth in GBA and contribute to the event of nationwide biosecurity capabilities and a extra resilient public well being system.
Hashtag: #ImmunoCure
https://immunocure.hk
https://www.linkedin.com/company/immuno-cure
The issuer is solely accountable for the content material of this announcement.
About the Center of International Innovation for Technology and Science (“CIITS”)
Center of International Innovation for Technology and Science (CIITS), because the worldwide headquarter of the Greater Bay Area National Center of Technology Innovation (GBA NCTI), is operated by Research Institute of Tsinghua University in Shenzhen (RITS). CIITS actively promotes the commercialization of know-how and scientific advances with abroad and home innovation establishments and groups, in addition to trade companions, specializing in areas resembling biomedicine, superior supplies and synthetic intelligence.
To be taught extra about CIITS, please comply with the WeChat official account: gh_425f503135d5
About Immuno Cure
Immuno Cure is a clinical-stage biotechnology group headquartered at Hong Kong Science Park. Immuno Cure is dedicated to the R&D of modern DNA vaccines and antibody immunotherapies for infectious ailments, inflammations, and cancers. Immuno Cure possesses two applied sciences: the “PD-1 Enhanced DNA Vaccine Platform” and the “Anti-Δ42PD1 Antibody”.
To be taught extra about Immuno Cure, please go to: www.immunocure.hk
** This press launch is distributed by Media OutReach Newswire via automated distribution system, for which the shopper assumes full duty. **
From left to right: Dr.Tengfei CAO, Deputy Director of CIITS; Mr. Tom LAU, Corporate Finance Director and Co-Founder of Immuno Cure; Dr. Renchen LIU, Executive Deputy Dean of Research Institute of Tsinghua University in Shenzhen and Director of CIITS; Dr. Xia JIN, CEO and Co-Founder of Immuno Cure; Prof. Zhiwei CHEN, Principal Scientific Advisor and Co-founder of Immuno Cure; Dr. Percy CHENG, Chairman and Co-Founder of Immuno Cure
Under the theme “Global Innovation Impact: The Year of Investment,” NIA is bringing collectively startups, buyers, corporates, and world companions to flip innovation into actual enterprise alternative and measurable impression.
BANGKOK, THAILAND – Media OutReach Newswire – 27 May 2026 – The National Innovation Agency (Public Organization), or NIA, below the Ministry of Higher Education, Science, Research and Innovation (MHESI), has formally launched SITE 2026. Organized below the idea “Global Innovation Impact: The Year of Investment,” the occasion is elevated to function a tangible platform of alternatives, bridging Thai improvements with world capital, companions, and networks.
Thailand Positions SITE 2026 as a Regional Platform Where Innovation Meets Investment
The expo will happen from June 25 – 27, 2026, at Paragon Hall, increasing its footprint to cowl Nex Hall on the fifth ground and the SCBx Next Stage on the 4th ground of Siam Paragon to accommodate the repeatedly rising actions and collaborative networks.
According to Dr. Krithpaka Boonfueng, Executive Director of NIA, the purpose is to create a platform the place alternative meets capital, and innovation meets world companions. In her view, innovation impression is now not outlined by novelty alone, however by the worth it creates and the measurable outcomes it may possibly ship.
That shift issues within the present regional context. For Thailand, the dialog is now not solely about constructing promising startups. It is about making innovation extra investable, extra related, and extra succesful of producing actual outcomes throughout enterprise and society.
NIA has framed SITE 2026 round a number of strategic drivers, together with future-focused applied sciences, investment-readiness innovation, world connectivity, multiplier results throughout the economic system, and stronger strategic alliances. Together, these are meant to assist place Thailand extra visibly throughout the regional and world innovation panorama.
The funding angle is particularly vital. NIA’s newest figures point out that startup funding in Thailand reached roughly USD 120 million in 2025, whereas capital prepared to be deployed inside Thailand’s innovation ecosystem exceeded USD 1 billion. Against that backdrop, SITE 2026 is being introduced as a well timed platform to join investable innovation with out there capital in a extra deliberate and market-oriented method.
From a programme perspective, SITE 2026 is structured to enchantment not solely to startups, but in addition to buyers, corporates, and innovation leaders wanting for deal circulate, market indicators, and partnership alternatives. Key options embrace:
- world boards and thought-leadership classes,
- showcases of 100 future-focused startups,
- 100 market-ready improvements,
- startup pitching alternatives,
- Business Matching classes,
- an International Pavilion,
- youth innovation platforms via Startup Thailand League,
- and cross-disciplinary collaboration via SYNC Design & Innovation and Maker Faire Bangkok.
For buyers and enterprise decision-makers, the strongest draw stands out as the occasion’s ambition to perform as a actual funding market. SITE 2026 is designed to carry Thai startups along with enterprise capital corporations, company enterprise capital arms, worldwide buyers, and strategic enterprise companions in a single built-in venue. It additionally opens broader regional connectivity via participation and collaboration from international locations together with Japan, South Korea, China, Hong Kong, and Singapore.
That positioning was echoed throughout the occasion’s launch dialogue, the place audio system from authorities, innovation finance, enterprise capital, and the startup neighborhood shared a typical view: innovation right this moment should lead to measurable outcomes— not solely in know-how growth, however in market entry, enterprise competitiveness, funding, and worldwide progress.
For Thailand, meaning strengthening its position not merely as a spot the place innovation occurs, however as a market the place innovation will be funded, scaled, and related internationally.
For regional buyers, corporates, and ecosystem leaders, SITE 2026 provides a more in-depth look at how Thailand is making an attempt to transfer in that route.
SITE 2026 shall be held from 25–27 June 2026 at Paragon Hall, Siam Paragon, Bangkok. Admission is free of cost. More info and registration can be found at website.nia.or.th.
Exploring Thailand’s Next Wave of Investable Innovation
SITE 2026 brings collectively startups, buyers, corporates, and world companions on one platform to discover enterprise alternative, market-ready innovation, and cross-border collaboration.
SITE 2026 is positioning Thailand as a regional platform the place innovation meets funding, bringing collectively startups, buyers, corporates, and world companions in Bangkok this June.
Hashtag: #SITE2026
The issuer is solely accountable for the content material of this announcement.
** This press launch is distributed by Media OutReach Newswire via automated distribution system, for which the shopper assumes full duty. **